DM
MDGL icon

Deerfield Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Deerfield Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,247
Closed -$289K – 406
2023
Q4 		$289K Buy
+1,247
New +$218K 0.01% 125

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Deerfield Management's MDGL Position: Q1 2024 in Review

Deerfield Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2024, closing a stake of 1,247 shares — an estimated $289K sold.

Deerfield Management first reported a position in MDGL in Q4 2023 and held it in 1 quarter. The position peaked at $289K in Q4 2023. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

  • Deerfield Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Deerfield Management sold 1,247 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $289K.
  • Deerfield Management first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Deerfield Management's Madrigal Pharmaceuticals position peaked at $289K in Q4 2023.
  • 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.